Retraction: Intersecting paths: Corporate and green innovation in Chinese firms-A panel cointegration analysis.
出版信息
PLoS One. 2025 Sep 4;20(9):e0331587. doi: 10.1371/journal.pone.0331587. eCollection 2025.
Abstract
摘要
相似文献
1
Retraction: Intersecting paths: Corporate and green innovation in Chinese firms-A panel cointegration analysis.
PLoS One. 2025 Sep 4;20(9):e0331587. doi: 10.1371/journal.pone.0331587. eCollection 2025.
2
Intersecting paths: Corporate and green innovation in Chinese firms-A penal cointegration analysis.
PLoS One. 2024 Jan 17;19(1):e0295633. doi: 10.1371/journal.pone.0295633. eCollection 2024.
3
Correction: Intersecting paths: Corporate and green innovation in Chinese firms-A penal cointegration analysis.
PLoS One. 2025 Jan 28;20(1):e0318610. doi: 10.1371/journal.pone.0318610. eCollection 2025.
4
Facilitating sustainable corporate growth in China: Examining the role of transition finance, green technology innovation, and ESG strategies in the path to sustainability.
J Environ Manage. 2025 Aug;389:126085. doi: 10.1016/j.jenvman.2025.126085. Epub 2025 Jun 9.
5
Carbon emissions trading and corporate green transformation: Evidence from a quasi-natural experiment in China.
J Environ Manage. 2025 Sep;391:126602. doi: 10.1016/j.jenvman.2025.126602. Epub 2025 Jul 16.
6
Environmental policy and corporate green innovation: The role of penalties, taxes, and subsidies in China.
J Environ Manage. 2025 Sep;392:126730. doi: 10.1016/j.jenvman.2025.126730. Epub 2025 Jul 30.
7
Innovation and valuation of Chinese born-global firms.
PLoS One. 2025 Jun 27;20(6):e0325214. doi: 10.1371/journal.pone.0325214. eCollection 2025.
8
Do environmental, social, and governance scores improve green innovation? Empirical evidence from Chinese-listed companies.
PLoS One. 2023 May 25;18(5):e0279220. doi: 10.1371/journal.pone.0279220. eCollection 2023.
9
Corporate litigation experience and innovation quality.
Sci Rep. 2025 Jul 2;15(1):22665. doi: 10.1038/s41598-025-08097-w.
10
Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China.
Front Public Health. 2025 Jul 30;13:1512148. doi: 10.3389/fpubh.2025.1512148. eCollection 2025.
本文引用的文献
1
Correction: Intersecting paths: Corporate and green innovation in Chinese firms-A penal cointegration analysis.
PLoS One. 2025 Jan 28;20(1):e0318610. doi: 10.1371/journal.pone.0318610. eCollection 2025.
2
Intersecting paths: Corporate and green innovation in Chinese firms-A penal cointegration analysis.
PLoS One. 2024 Jan 17;19(1):e0295633. doi: 10.1371/journal.pone.0295633. eCollection 2024.
Zotero 插件